OpenAI acquires drug-discovery coordination platform Orchestra Bio
OpenAI has acquired Orchestra Bio and plans to fold its team and technology into Rosalind, its life-sciences research models and tools. The two aim to build agents that connect a scientific finding to the research, decisions and next steps needed to move a drug candidate forward. Orchestra's agents track study progress, flag activities and timelines hit by problems, and gather information and compare options for scientists and project leads to decide on.
Why it matters: OpenAI is pairing Orchestra Bio's drug-development coordination platform with Rosalind, aiming for agents that link scientific discovery to R&D execution.